Mylan (MYL), MPP Enter Agreement for Expanded HCV Medicines Access
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks rattled, Treasuries rally after Israel attacks Iran
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Oil surges as reports of Israeli strike on Iran roil markets
- Reports of Israeli attack on Iran spark rush to yen, Swiss franc
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
BTIG Positive on Mylan's (MYL) Asthma/COPD Opportunity in 2017; Affirms at 'Buy'
November 28, 2016 11:06 AM ESTBTIG reaffirms Mylan N.V. (Nasdaq: MYL) with a Buy rating and $55 price target, offering up a look into 2017 for the company.
The firm commented on Monday: Heading into next year, we believe a key generic product opportunity could be Advair (fluticasone/salmeterol for the treatment of asthma/COPD, a $2 billion branded market opportunity in... More
